Parkinson's Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2021 Mar 16

PMID 33725345

Citations 4

Authors

Biswadeep Das

Sriya Priyadarshini Dash

Swabhiman Mohanty

Paritosh Patel

Affiliations

Soon will be listed here.

Abstract

Mitochondrial bioenergetics is vital for the proper functioning of cellular compartments. Impairments in mitochondrial DNA encoding the respiratory chain complexes and other assisting proteins, accumulation of intracellular reactive oxygen species, an imbalance in cellular calcium transport, or the presence of organic pollutants, high fat-ketogenic diets or toxins, and advancing age can result in complex disorders, including cancer, metabolic disease, and neurodegenerative disorders. Such manifestations are distinctly exhibited in several age-related neurodegenerative diseases, such as in Parkinson's disease (PD). Defects in complex I along with perturbed signaling pathways is a common manifestation of PD. Impaired oxidative phosphorylation could increase the susceptibility to PD. Therefore, unraveling the mechanisms of mitochondrial complexes in clinical scenarios will assist in developing potential early biomarkers and standard tests for energy failure diagnosis and assist to pave a new path for targeted therapeutics against PD.

Citing Articles

Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells.

Benoit R, Zagrodnik J, Carew S, Moore C Immunohorizons. 2024; 8(9):652-667.

PMID: 39259208 PMC: 11447691. DOI: 10.4049/immunohorizons.2400045.

Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.

Banerjee P, Saha I, Sarkar D, Maiti A Neurotox Res. 2022; 40(3):847-873.

PMID: 35386026 DOI: 10.1007/s12640-022-00501-x.

Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Mishra A, Bandopadhyay R, Singh P, Mishra P, Sharma N, Khurana N Metab Brain Dis. 2021; 36(7):1591-1626.

PMID: 34387831 DOI: 10.1007/s11011-021-00806-4.

Circulating CircRNAs Panel Acts as a Biomarker for the Early Diagnosis and Severity of Parkinson's Disease.

Zhong L, Ju K, Chen A, Cao H Front Aging Neurosci. 2021; 13:684289.

PMID: 34276342 PMC: 8281126. DOI: 10.3389/fnagi.2021.684289.

References

Elfawy H, Das B . Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. Life Sci. 2018; 218:165-184. DOI: 10.1016/j.lfs.2018.12.029. View

Shoubridge E . Nuclear genetic defects of oxidative phosphorylation. Hum Mol Genet. 2001; 10(20):2277-84. DOI: 10.1093/hmg/10.20.2277. View

Zecca L, Youdim M, Riederer P, Connor J, Crichton R . Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004; 5(11):863-73. DOI: 10.1038/nrn1537. View

Castello P, Drechsel D, Patel M . Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem. 2007; 282(19):14186-93. PMC: 3088512. DOI: 10.1074/jbc.M700827200. View

Zuo L, Motherwell M . The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene. 2013; 532(1):18-23. DOI: 10.1016/j.gene.2013.07.085. View

Gorell J, Peterson E, Rybicki B, Johnson C . Multiple risk factors for Parkinson's disease. J Neurol Sci. 2004; 217(2):169-74. DOI: 10.1016/j.jns.2003.09.014. View

Wirdefeldt K, Adami H, Cole P, Trichopoulos D, Mandel J . Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26 Suppl 1:S1-58. DOI: 10.1007/s10654-011-9581-6. View

Schapira A, Jenner P . Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011; 26(6):1049-55. DOI: 10.1002/mds.23732. View

Canta A, Chiorazzi A, Carozzi V, Meregalli C, Oggioni N, Bossi M . Age-related changes in the function and structure of the peripheral sensory pathway in mice. Neurobiol Aging. 2016; 45:136-148. DOI: 10.1016/j.neurobiolaging.2016.05.014. View

10.

Wyss-Coray T . Ageing, neurodegeneration and brain rejuvenation. Nature. 2016; 539(7628):180-186. PMC: 5172605. DOI: 10.1038/nature20411. View

11.

Kanthasamy A, Kitazawa M, Kanthasamy A, Anantharam V . Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. Neurotoxicology. 2005; 26(4):701-19. DOI: 10.1016/j.neuro.2004.07.010. View

12.

Lightowlers R, Taylor R, Turnbull D . Mutations causing mitochondrial disease: What is new and what challenges remain?. Science. 2015; 349(6255):1494-9. DOI: 10.1126/science.aac7516. View

13.

Schapira A . Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 2007; 14(7):1261-6. DOI: 10.1038/sj.cdd.4402160. View

14.

Devi L, Raghavendran V, Prabhu B, Avadhani N, Anandatheerthavarada H . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283(14):9089-100. PMC: 2431021. DOI: 10.1074/jbc.M710012200. View

15.

Gu G, Reyes P, Golden G, Woltjer R, Hulette C, Montine T . Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol. 2002; 61(7):634-9. DOI: 10.1093/jnen/61.7.634. View

16.

Wallace D, Shoffner J, Watts R, Juncos J, Torroni A . Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol. 1992; 32(1):113-4. DOI: 10.1002/ana.410320123. View

17.

Palacino J, Sagi D, Goldberg M, Krauss S, Motz C, Wacker M . Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem. 2004; 279(18):18614-22. DOI: 10.1074/jbc.M401135200. View

18.

Jeong E, Chung J, Liu H, Go Y, Gladstein S, Farzaneh-Far A . Role of Mitochondrial Oxidative Stress in Glucose Tolerance, Insulin Resistance, and Cardiac Diastolic Dysfunction. J Am Heart Assoc. 2016; 5(5). PMC: 4889180. DOI: 10.1161/JAHA.115.003046. View

19.

Kalani K, Yan S, Yan S . Mitochondrial permeability transition pore: a potential drug target for neurodegeneration. Drug Discov Today. 2018; 23(12):1983-1989. PMC: 6449145. DOI: 10.1016/j.drudis.2018.08.001. View

20.

Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H . Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem. 1990; 55(5):1810-2. DOI: 10.1111/j.1471-4159.1990.tb04973.x. View